CEMI Key Statistics, Chart & Performance
The current stock price of CEMI is 0.455 USD. In the past month the price increased by 5.79%. In the past year, price decreased by -20.97%.
CEMI Latest News, Press Relases and Analysis
CEMI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 18.87 | 15.08B | ||
| SOLV | SOLVENTUM CORP | 14.41 | 14.85B | ||
| ALGN | ALIGN TECHNOLOGY INC | 15.61 | 10.83B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.69 | 5.00B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.82 | 3.88B | ||
| HAE | HAEMONETICS CORP/MASS | 16.83 | 3.78B | ||
| ICUI | ICU MEDICAL INC | 18.42 | 3.62B | ||
| XRAY | DENTSPLY SIRONA INC | 7.03 | 2.22B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.39 | 1.69B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.29B | ||
| NEOG | NEOGEN CORP | 19.73 | 1.29B | ||
| EMBC | EMBECTA CORP | 4.14 | 719.43M |
Related stock screener links
About CEMI
Company Profile
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. The company is headquartered in Medford, New York and currently employs 188 full-time employees. The company went IPO on 2000-10-18. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. The company is also targeting lateral flow test solutions for infectious diseases.
Company Info
CHEMBIO DIAGNOSTICS INC
555 Wireless Blvd, 3661 Horseblock Road
Medford NEW YORK 11788 US
CEO: Richard L. Eberly
Employees: 188
Phone: 16319241135.0
CHEMBIO DIAGNOSTICS INC / CEMI FAQ
What does CHEMBIO DIAGNOSTICS INC do?
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. The company is headquartered in Medford, New York and currently employs 188 full-time employees. The company went IPO on 2000-10-18. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. The company is also targeting lateral flow test solutions for infectious diseases.
What is the current price of CEMI stock?
The current stock price of CEMI is 0.455 USD. The price increased by 0.22% in the last trading session.
What is the dividend status of CHEMBIO DIAGNOSTICS INC?
CEMI does not pay a dividend.
What is the ChartMill rating of CHEMBIO DIAGNOSTICS INC stock?
CEMI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in CHEMBIO DIAGNOSTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CEMI.
CEMI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CEMI. When comparing the yearly performance of all stocks, CEMI is one of the better performing stocks in the market, outperforming 82.43% of all stocks.
CEMI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CEMI. CEMI has a bad profitability rating. Also its financial health evaluation is rather negative.
CEMI Financial Highlights
Over the last trailing twelve months CEMI reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 45.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CEMI Forecast & Estimates
6 analysts have analysed CEMI and the average price target is 8.16 USD. This implies a price increase of 1693.41% is expected in the next year compared to the current price of 0.455.